© 2024 GE HealthCare. Edison, Vscan Air, SignalMax, XDclear and Caption AI are trademarks of GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Third party trademarks are the property of their respective owners. DICOM is the registered trademark of the National Electrical Manufacturers Association for its standards publications relating to digital communications of medical information. DICOMweb is a trademark of the National Electrical Manufacturers Association, Secretariat for the DICOM Standards Committee. Commercial availability of GE HealthCare medical systems is subject to meeting local requirements in a given country or region. Contact a GE HealthCare Representative for more information. Content on this site is intended only for healthcare providers.

MRI-guided Transurethral Ultrasound Ablation (TULSA) is a minimally-invasive treatment for patients with localized prostate cancer, where the therapeutic endpoint is prostate ablation through thermal coagulation. It combines Magnetic Resonance Imaging (MRI) based planning, monitoring, and treatment control with transurethral delivery of therapeutic ultrasound to ablate prostate tissue from the inside out.

The RCM system is a software-controlled, pneumatically driven robotic manipulator for MR guided prostate biopsy in a clinical environment. An optimal diagnosis of prostate cancer requires accurate retrieval and pathology of tissue samples. Magnetic resonance imaging can be used to visualize suspected regions within the prostate gland.

cvi42 is intended to be used for viewing, post-processing and quantitative evaluation of cardiovascular magnetic resonance images in a Digital Imaging and Communications in Medicine (DICOM) Standard format.